In conclusion, anticytotoxic CTLA-4, PD-1/PD-L1 checkpoint inhibitors have a relevant clinical value in a large number of solid tumors (Table 1 and Figure 2), becoming a new pillar in cancer therapy but with an efficacy limited by intrinsic or acquired resistance to these agents. The gene discussed is CD274; the disease is cancer.